Grants
Grants are listed by donor, with the percentage of total EFNA funding shown. These should be considered alongside funding in other years as the figures below merely show the ‘snapshot’ of funds received as at 31 December in the year concerned.
The total amount of EFNA funding for each year may be found in the audited accounts but these accounts do not include any ‘donations in kind’ such as staff secondment.
In the tables of percentages “EFNS” is the acronym for European Federation of Neurological Societies.
| Source | Grant/value of donation in kind | % of Total Funding & other support |
|---|---|---|
| Novartis | € 52,873.37 | 17.14 |
| Britannia | € 6,473.95 | 2.10 |
| GE Healthcare | € 13,065.53 | 4.23 |
| Solvay | € 53,600.16 | 17.37 |
| TEVA | € 1,000.00 | 0.32 |
| GSK | € 30,689.33 | 9.95 |
| Genus Pharm | € 20,963.37 | 6.79 |
| European Commission | € 1,906.52 | 0.62 |
| Pfizer | € 42,580.00 | 13.80 |
| Boehringer Ingelheim | € 60,700.00 | 19.67 |
| EFNS | € 23,000.00 | 7.45 |
| Other | € 1,711.89 | 0.55 |
| Source | Grant/value of donation in kind | % of Total Funding & other support |
|---|---|---|
| European Commission (Restricted) | € 3,521 | 2.08 |
| European Commission (Restricted) | € 52,070 | 30.79 |
| Boehringer (Restricted) | € 40,000 | 23.65 |
| GSK (Unrestricted) | € 28,673 | 16.95 |
| Novartis (Restricted) | € 20,209 | 11.95 |
| EFNS (Staff secondment) | € 23,000 | 13.60 |
| Other | € 1,645 | 0.97 |
| Source | % of Total Funding & other support |
|---|---|
| Novartis (Restricted) | 2.62 |
| Movers and Shakers (UK Charity) | 15.40 |
| GSK (Restricted) | 1.93 |
| GE Healthcare (Restricted) | 15.03 |
| GSK (Unrestricted) | 14.48 |
| Alexion Pharma | 20.21 |
| GSK (Restricted) | 15.56 |
| European Parkinson's Disease | 0.39 |
| Eli Lilly (Resticted) | 2.05 |
| EFNS (Staff secondment) | 12.07 |
| Other | 0.26 |
| Source | % of Total Funding & other support |
|---|---|
| Britannia Pharma (Restricted) | 1.36 |
| Valeant (Restricted) | 1.37 |
| GSK (Unrestricted) | 2.72 |
| European Commission (Restricted) | 83.49 |
| Schering (Restricted) | 3.80 |
| MSD (Restricted) | 2.76 |
| Serono (Restricted) | 0.38 |
| EFNS (Staff secondment) | 3.92 |
| Other | 0.21 |
| Source | % of Total Funding & other support |
|---|---|
| GSK (Unrestricted) | 9.9 |
| Novartis (Unrestricted) | 29.6 |
| Novartis (Restricted) | 24.3 |
| MSD (Unrestricted) | 9.9 |
| EFNS (Staff secondment) | 22.4 |
| Other | 3.9 |